Acute hyperhomocysteinemia impairs endothelium function in subjects with type 2 diabetes mellitus.
The objective of the present study was to examine the effect of acute, methionine-induced hyperhomocysteinemia (HHCY) on endothelial function and indices of arterial stiffness in subjects with type 2 diabetes mellitus (T2DM). A total of 30 subjects with T2DM, free of macrovascular disease were examined in a crossover study. L-methionine (M) (0.1 g/kg) and water (W) load were given in random order with an interval of about 1 week in between. Endothelial function was assessed by flow-mediated vasodilation (FMD). Arterial stiffness was assessed by determination of augmentation index (AI). Measurements were performed in the fasting state, 1, 2 and 3 h after the M or the W load. Total plasma homocysteine (HCY) levels did not change after W administration, while M administration resulted in a significant increase in HCY concentrations at 3 h. FMD throughout the experiment expressed as area under the curve (AUC) was significantly lower after the M than after the W load. Consistent with impairment in endothelial function, the AUC of AI was significantly higher after the M than after the W administration. Acute HHCY impairs endothelial function and increases arterial stiffness in patients with T2DM. This effect is probably mediated by a reduction of nitric oxide bioavailability in endothelium.
Doupis
J
J
First Department of Propaedeutic Medicine, Athens University Medical School, Athens, Greece.
Eleftheriadou
I
I
Kokkinos
A
A
Perrea
D
D
Pavlatos
S
S
Gonis
A
A
Katsilambros
N
N
Tentolouris
N
N
D000368:Aged; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001916:Brachial Artery / Q000187:drug effects / Q000503:physiopathology; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000503:physiopathology*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000139:chemically induced* / Q000150:complications / Q000503:physiopathology; D008183:Luteal Phase; D008297:Male; D008715:Methionine / Q000009:adverse effects* / Q000097:blood; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood; D014664:Vasodilation / Q000187:drug effects*; D014867:Water / Q000008:administration & dosage
D001786:Blood Glucose; D014280:Triglycerides; D014867:Water; D006710:Homocysteine; D002784:Cholesterol; D008715:Methionine